Skip Navigation

JNCI Journal of the National Cancer Institute 2000 92(19):1555; doi:10.1093/jnci/92.19.1555
© 2000 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Reynolds, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Reynolds, T.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 92, No. 19, 1555, October 4, 2000
© 2000 Oxford University Press

NEWS

How Does a Drug Get to Phase III Trials?

Tom Reynolds

NCI’s Drug Development Group (DDG; which replaced the Decision Network Committee in January 2000) handles most decisions on whether to continue moving investigational agents along the pipeline from preclinical testing to Investigational New Drug application filing to phase I trials. DDG is co-chaired by the associate . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?